Acquisition Target Lannett is in play for a potential acquisition by Aurobindo Pharma US for 250M, signaling strategic consolidation in generic manufacturing and a buyer open to integrating Lannett’s product portfolio and facilities.

Litigation & Settlements Recent multistate settlements related to price practices could pose risk but also signals a heightened focus on compliance; present opportunities to offer transparency, compliance consulting, and pricing governance services to maintain market access.

Product Expansion Lannett has diversified into complex generics and biosimilars including insulin glargine and evothyroxine capsules, suggesting appetite for additional specialty programs and partnerships in high-value segments.

Global Partnerships Past collaborations with Ypsomed and partner networks indicate openness to strategic alliances; explore co-development or licensing agreements for device-enabled biologics or convenient delivery formats.

Scale & Capacity With substantial in-house capacity for oral solids and liquids, Lannett could be a candidate for contract manufacturing expansions, fill-finish, and supply chain optimization services to support growth and geographic expansion.